CHTP Share Price

Open 6.55 Change Price %
High 6.67 1 Day -0.03 -0.46
Low 6.52 1 Week 0.00 0.00
Close 6.52 1 Month 0.00 0.00
Volume 6150167 1 Year 0.00 0.00
52 Week High 34.85
52 Week Low 0.00
CHTP Important Levels
Resistance 2 6.66
Resistance 1 6.60
Pivot 6.57
Support 1 6.44
Support 2 6.38
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ETRM 0.07 0.00%
AAPL 113.86 1.55%
AAPL 113.86 1.55%
More..
NASDAQ USA Top Gainers Stocks
HTCO 11.00 62.96%
LOCM 0.09 50.00%
OPXA 1.21 40.70%
QKLS 0.18 38.46%
ZAZA 0.08 33.33%
MOSY 0.46 31.43%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PPHM 0.40 25.00%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
BGMD 0.05 -37.50%
More..

Chelsea Therapeutics International, Ltd. (NASDAQ: CHTP)

CHTP Technical Analysis 5
As on 23rd Jun 2014 CHTP Share Price closed @ 6.52 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 4.34 & Strong Buy for SHORT-TERM with Stoploss of 5.91 we also expect STOCK to react on Following IMPORTANT LEVELS.
CHTP Target for December
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
CHTP Other Details
Segment EQ
Market Capital 104583288.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.chelseatherapeutics.com
CHTP Address
CHTP
3530 Toringdon Way
Suite 200
Charlotte, NC 28277
United States
Phone: 704-341-1516
CHTP Latest News
Interactive Technical Analysis Chart Chelsea Therapeutics International, Ltd. ( CHTP NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Chelsea Therapeutics International, Ltd.
CHTP Business Profile
Chelsea Therapeutics International, Ltd. is a development stage pharmaceutical company that focuses on acquiring, developing and commercializing products for the treatment of a variety of human diseases. The Company is developing a therapeutic agent for the treatment of symptomatic neurogenic orthostatic hypotension (NOH), associated with primary autonomic failure and falls related to NOH in Parkinson�s Disease (PD), as well as other norepinephrine-related conditions and diseases, including intradialytic hypotension (IDH), fibromyalgia, adult attention deficit hyperactivity disorder (ADHD), chronic fatigue syndrome (CFS), freezing of gait in PD and Down syndrome. In addition, the Company is developing a portfolio of metabolically inert antifolates for the treatment of rheumatoid arthritis and is exploring potential applications in multiple other autoimmune disorders.